AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02354612
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: companion therapy selection depends on companion therapy used in the parent study
Trial: NCT02354612
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: companion therapy selection depends on companion therapy used in the parent study
Trial: NCT06248099
Drug: Nebivolol-Test product
RxNorm normalized name: nebivolol Oral Product
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test-Product: Nebivolol tablets 5 mg Manufactured by: Hetero Labs Limited, India
Trial: NCT06248099
Drug: Nebivolol-Reference product
RxNorm normalized name: nebivolol Oral Product
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference-product: Nebilet tablets 5 mg Manufactured by: BERLIN CHEMIE AG, Germany
Trial: NCT04026880
Drug: Testosterone Enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
Trial: NCT05189873
Drug: HRT
RxNorm normalized name: femhrt
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the HRT group, from the second day of the cycle, the participant receives 2 mg of estradiol daily and this drug is increased to 6 mg per day in three days.Ten days later, they undergo vaginal ultrasound to check the thickness of the endometrium. If the thickness of the endometrium is greater than 8 mm, inject able progesterone is prescribed and the patient is a candidate for FET transfer. If the thickness is less than 7 mm, it is necessary to increase the dose of estradiol and continue treatment with it. The patient undergoes vaginal ultrasound every three days and if the desired thickness does not reach 21 days after the start of the cycle, the cycle is canceled
Trial: NCT05562869
Drug: Belatacept 250 Milligram Intravenous Powder for Solution
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)
Trial: NCT05525260
Drug: Limonene capsule
DrugBank: Limonene, (+/-)- (DB19146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus foods rich in D-limonene were forbiden 2 days before taking the drug (washout period), which was maintained after taking the drug.Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
Trial: NCT05525260
Drug: Limonene capsules(Placebo)
DrugBank: Limonene, (+/-)- (DB19146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limonene capsules(Placebo)
Trial: NCT05486416
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol for induction of general anesthesia
Trial: NCT03866499
Drug: BPI-7711
RxNorm normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg, oral, QD
Trial: NCT03866499
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg, oral, QD
Trial: NCT05416073
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PCIA formula：100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
Trial: NCT00344695
Drug: bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05443646
Drug: HLX10
RxNorm normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W
Trial: NCT04021550
Drug: Telmisartan 80mg
RxNorm normalized name: TELMISARTAN 80MG TAB
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this group will receive 80mg/day of Telmisartan (an angiotensin receptor blocker). Treatments will be administered in pre-packaged blister packages. Subjects will take Telmisartan once per day for 6 weeks.
Trial: NCT06070636
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Trial: NCT06070636
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg intravenously every 32 weeks
Trial: NCT05216497
Drug: Ingavirin®, 90 mg capsules
DrugBank: Ingavirin (DB11944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-180 mg/day for 7 days on top of standard therapy
Trial: NCT04639271
Drug: Pyrotinib Plus And
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib::400mg/d,qd,po
Trial: NCT04639271
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle
Trial: NCT04639271
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abraxane 125mg/M2, qw iv
Trial: NCT03177746
Drug: Dapoxetine/Tadalafil 30/20 mg film coated tablet
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.~Study drug should not be used more than 1 tablet every 24 hours during the treatment.
Trial: NCT05096390
Drug: Axitinib Oral Tablet [Inlyta]
RxNorm normalized name: axitinib Oral Tablet [Inlyta]
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib 5 up to 10mg twice a day
Trial: NCT05096390
Drug: Pembrolizumab Injection [Keytruda]
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab intravenously over 30 min minutes at 200 mg every 3 weeks
Trial: NCT06389617
Drug: supraclavicular block with 20mls of Ropivacaine 0.5% and Intravenous administered dexamethasone
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparing the onset of sensory, motor block, duration of motor block and analgesic duration
Trial: NCT05437601
Drug: Astaxanthin Oral Capsule
RxNorm normalized name: astaxanthin Oral Capsule
DrugBank: Astaxanthin (DB06543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg oral astaxanthin daily for 8 weeks
Trial: NCT06349486
Drug: vonoprazan, amoxicillin, tripotassium dicitrate bismuthate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bismuth-amoxicillin-vonoprazan triple therapy
Trial: NCT06349486
Drug: vonoprazan, amoxicillin
RxNorm normalized name: vonoprazan, amoxicillin and metronidazole
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vonoprazan-amoxicillin dual therapy
Trial: NCT05303220
Drug: Branebrutinib
RxNorm normalized name: Branebrutinib
DrugBank: Branebrutinib (DB15347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05444218
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
Trial: NCT05444218
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
Trial: NCT04893161
Drug: Belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.
Trial: NCT06118203
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide in addition to standard of care
Trial: NCT04955340
Drug: [14C]-resminostat
DrugBank: Resminostat (DB12392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single dose of 400 mg \[14C\]-resminostat
Trial: NCT05753371
Drug: Metformin Hydrochloride 500 MG
RxNorm normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Trial: NCT06063018
Drug: RC48 + Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC48: intravenous drip, 2mg/kg, D1, repeated once every 2 weeks. Tislelizumab: intravenous drip, fixed dose 600 mg, D1, repeated once every 6 weeks.
Trial: NCT06433128
Drug: Fosmanogepix solution for infusion
RxNorm normalized name: Duo Fusion
DrugBank: Fosmanogepix (DB15183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration
Trial: NCT06433128
Drug: Fosmanogepix 400 mg tablets
RxNorm normalized name: Fosmanogepix
DrugBank: Fosmanogepix (DB15183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmanogepix 400 mg tablets for oral administration
Trial: NCT06211023
Drug: SHR-1921
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1921
Trial: NCT06211023
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin AUC 4
Trial: NCT06211023
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin AUC 5
Trial: NCT05741359
Drug: CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
Trial: NCT06211023
Drug: platinum-based doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: platinum-based doublet chemotherapy
Trial: NCT04535024
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starts within one week upon SABR completion: 200mg, d1, q3w; Continued until disease progression, unacceptable toxicity or patient withdrawal.
Trial: NCT05852769
Drug: BMS-986196
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05852769
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05852769
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05852769
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05852769
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04939467
Drug: Pirfenidone 267 mg Oral Tablet
RxNorm normalized name: Pirfenidone 267 mg oral tablet
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed sequence use of active product, TID
Trial: NCT04939467
Drug: Nintedanib 150 mg Oral Capsule
RxNorm normalized name: nintedanib 150 MG Oral Capsule
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed sequence use of active product, BID
Trial: NCT04939467
Drug: BLD-0409 750 mg Oral Tablet
RxNorm normalized name: BLD-0409
DrugBank: Cudetaxestat (DB18203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed sequence use of active product, QD
Trial: NCT00111410
Drug: Anakinra (r-metHuIL-1ra)
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04825561
Drug: AD-2081
RxNorm normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 24weeks
Trial: NCT05670015
Drug: Low dosage selective alpha-2 receptor agonists topical eyedrop
RxNorm normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.
Trial: NCT05670015
Drug: High dosage selective alpha-2 receptor agonists topical eyedrop
RxNorm normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
Trial: NCT04702360
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IVA monotablet for oral administration.
Trial: NCT04757662
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil is commercially available and will be purchased by the Siteman Cancer Center and distributed to participants free of charge.
Trial: NCT05266196
Drug: Seclidemstat
RxNorm normalized name: Seclidemstat
DrugBank: Seclidemstat (DB17117)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment assigned as per parent protocol
Trial: NCT05571345
Drug: PF614
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PF614 capsules (50 mg or 100 mg)
Trial: NCT05571345
Drug: Oxycodone Hydrochloride 40 mg
RxNorm normalized name: oxycodone hydrochloride 40 MG
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral 20 mg tablets (two each)
Trial: NCT04531865
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab: 375 mg/m2 intravenously on day 0 and day 7
Trial: NCT04531865
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
Trial: NCT04830735
Drug: Dasatinib Anhydrous
RxNorm normalized name: Dasatinib anhydrous
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00348400
Drug: Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05559008
Drug: Azacitidine Injection
RxNorm normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
Trial: NCT05559008
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
Trial: NCT05559008
Drug: Linperlisib
RxNorm normalized name: Linperlisib
DrugBank: Linperlisib (DB17235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes
Trial: NCT05559008
Drug: Tucidinostat
RxNorm normalized name: tucidinostat
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
Trial: NCT05559008
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab and Apatinib will be administered in T3.2 subtypes
Trial: NCT05559008
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab and Apatinib will be administered in T3.2 subtypes
Trial: NCT04789304
Drug: BI 1595043
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1595043
Trial: NCT04789304
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam
Trial: NCT05079451
Drug: 10-1074-LS
RxNorm normalized name: sulfacetamide
DrugBank: Sulfacetamide (DB00634)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-1074-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
Trial: NCT05313009
Drug: Sotorasib and Tarloxotinib
RxNorm normalized name: sotorasib
DrugBank: Tarloxotinib (DB14944)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sotorasib 960 mg PO daily + tarloxotinib 150 mg/m2 IV weekly
Trial: NCT05313009
Drug: Sotorasib and Tarloxotinib
RxNorm normalized name: sotorasib
DrugBank: Tarloxotinib (DB14944)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sotorasib 960 mg PO daily + tarloxotinib IV weekly at the combination RP2D (RP2Dc).
Trial: NCT04821687
Drug: Ongentys 50mg
RxNorm normalized name: Ongentys 50mg Capsule
DrugBank: Opicapone (DB11632)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI
Trial: NCT05573230
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT05573230
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05418829
Drug: AT-007
RxNorm normalized name: AT-007
DrugBank: Gavorestat (DB16707)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-007 20 mg/kg once daily
Trial: NCT04831710
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab,200mg, ivd, d1
Trial: NCT04831710
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Chidamide,30mg,po,biw,d1-21
Trial: NCT06429904
Drug: Nimotuzumab+ NALIRIFOX
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Nimotuzumab Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg, 600mg, 400mg on Day 1, 8, 15, respectively, 28 days as a cycle, up to 6 cycles.~Other Names: h-R3~Drug: NALIRIFOX Patients will receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle, up to 6 cycles.~Other Names: NALIRIFOX
Trial: NCT05440799
Drug: BI 1819479
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1819479
Trial: NCT05232552
Drug: Anlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anlotinib was administered orally 12mg daily for 14 days concurrent with inductive chemotherapy (TP ) for 3 cycles and definitive chemoradiation for additional 2 cycles
Trial: NCT03787082
Drug: Nitrates
RxNorm normalized name: Nitrates
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg/11.18 mmol, oral
Trial: NCT03787082
Drug: Chlorhexidine Gluconate Mouthwash
RxNorm normalized name: chlorhexidine gluconate Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute